Nanotechnology-Based Theranostic Strategies for Triple-Negative Breast Cancer
ACS Applied Bio Materials · 02.11.2026 · 9 (21) · 10026-10048
DOI: 10.1021/acsabm.6c01549 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Applied Bio Materials, online erschienen am 19.10.2026. Verfasst von Liufei Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang471000, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Theranostic Nanomedicine, Antineoplastic Agents, Biocompatible Materials. Die Arbeit nennt 160 Literaturangaben. Gefördert von: Henan Provincial Soft Science Project Application, Key specialized research and development breakthrough of Henan province, Heluo Youth Talent Support Project.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a heterogeneous type of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Because of the lack of ER, PR, and HER2 targets, TNBC is unsuitable for endocrine therapy and HER2-targeted therapy and is associated with a higher risk of early recurrence, distant metastasis, and poorer prognosis than many other breast cancer subtypes, particularly in advanced or metastatic disease. Although surgery, chemotherapy, radiotherapy, and immunotherapy have been used for TNBC treatment, current therapeutic outcomes remain limited by systemic toxicity, high recurrence rates, insufficient tumor selectivity, and acquired drug resistance. Therefore, novel approaches are needed to address these challenges. Nanomaterials with optical, magnetic, catalytic, and porous properties can serve as imaging contrast agents, drug carriers, photosensitizers, nanozymes, radiosensitizers, and multifunctional theranostic platforms. However, the clinical translation of TNBC-oriented nanomedicines remains limited because of insufficient patient stratification, variable tumor accumulation, unclear long-term biosafety, and challenges in scalable manufacturing. To improve the clinical application of nanotechnology in TNBC treatment, it is imperative to integrate nanotechnology with existing clinical diagnosis and treatment methods. This integration may help overcome the limitations of individual diagnostic and therapeutic methods, enhance tumor targeting and radiotherapy sensitivity, reduce cytotoxicity and drug resistance, and maximize the efficiency of multimodal diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang471000, China.
- Office of Science and Technology, Henan University of Science and Technology, Luoyang471000, China.
ORCID-Profile: Jing Li
Förderung
- Henan Provincial Soft Science Project Application
- Key specialized research and development breakthrough of Henan province
- Heluo Youth Talent Support Project
Zitieren
APA
Yang, L., Wang, T., Wu, Y., Zhuang, R., Zhao, W., Li, X., Tu, H., Wang, J., Zu, X., & Li, J. (2026). Nanotechnology-Based Theranostic Strategies for Triple-Negative Breast Cancer. ACS Applied Bio Materials, 9(21), 10026-10048. https://doi.org/10.1021/acsabm.6c01549
Vancouver
Yang L, Wang T, Wu Y, Zhuang R, Zhao W, Li X, et al. Nanotechnology-Based Theranostic Strategies for Triple-Negative Breast Cancer. ACS Applied Bio Materials. 2026;9(21):10026-10048. doi:10.1021/acsabm.6c01549
BibTeX
@article{Yang2026,
author = {Yang, Liufei and Wang, Tong and Wu, Yongping and Zhuang, Rongning and Zhao, Wenqian and Li, Xueao and Tu, Hui and Wang, Jing and Zu, Xiangyang and Li, Jing},
title = {Nanotechnology-Based Theranostic Strategies for Triple-Negative Breast Cancer},
journal = {ACS Applied Bio Materials},
year = {2026},
volume = {9},
number = {21},
pages = {10026--10048},
doi = {10.1021/acsabm.6c01549}
}
EUVIMED